Skip to content

Enhanced mindfulness based stress reduction (MBSR+) in episodic migraine: a randomized clinical trial with MRI outcomes

David A Seminowicz, Shana A B Burrowes, A. Kearson, Jing Zhang, Samuel R Krimmel, L. Samawi, Andrew J. Furman, Michael L. Keaser, Neda F Gould, T. Magyari, Linda White, Olga Goloubeva, Madhav Goyal, B. Peterlin, Jennifer A. Haythornthwaite

Pain March 13, 2020 DOI: 10.1097/j.pain.0000000000001860 (opens in new tab)

Study at a glance

AI-extracted from the abstract
Characteristics Randomized, assessor-blind, clinical trial Peer reviewed
Sample size 98
Population Adults with episodic migraine recruited at a single academic center
Interventions Enhanced mindfulness-based stress reduction (MBSR+) Stress management for headache (SMH)
Duration 8-week weekly sessions then 8-week bi-weekly sessions; primary outcome at 20 weeks; follow-up at 52 weeks
Topics Meditation
Key findings MBSR+ reduced headache days more than SMH at 20 weeks, with a greater response rate and disability improvement, but no differences at 52 weeks or in MRI outcomes.

Abstract

We aimed to evaluate the efficacy of an enhanced mindfulness based stress reduction (MBSR+) versus stress management for headache (SMH). We performed a randomized, assessor-blind, clinical trial of 98 adults with episodic migraine recruited at a single academic center comparing MBSR+ (n=50) to SMH (n=48). MBSR+ and SMH were delivered weekly by group for 8 weeks, then bi-weekly for another 8 weeks. The primary clinical outcome was reduction in headache days from baseline to 20 weeks. MRI outcomes included activity of left dorsolateral prefrontal cortex (DLPFC) and cognitive task network during cognitive challenge, resting state connectivity of right dorsal anterior insula (daINS) to DLPFC and cognitive task network, and gray matter volume of DLPFC, daINS, and anterior midcingulate. Secondary outcomes were headache-related disability, pain severity, response to treatment, migraine days, and MRI whole-brain analyses. Reduction in headache days from baseline to 20 weeks was greater for MBSR+ (7.8 [95%CI, 6.9–8.8] to 4.6 [95%CI, 3.7–5.6]) than for SMH (7.7 [95%CI 6.7–8.7] to 6.0 [95%CI, 4.9–7.0]) (P=0.04). 52% of the MBSR+ group showed a response to treatment (50% reduction in headache days) compared with 23% in the SMH group (P=0.004). Reduction in headache-related disability was greater for MBSR+ (59.6 [95%CI, 57.9–61.3] to 54.6 [95%CI, 52.9–56.4]) than SMH (59.6 [95%CI, 57.7–61.5] to 57.5 [95%CI, 55.5–59.4]) (P=0.02). There were no differences in clinical outcomes at 52 weeks or MRI outcomes at 20 weeks, although changes related to cognitive networks with MBSR+ were observed. MBSR+ is an effective treatment option for episodic migraine.

Comparable studies

Other randomized controlled trials on meditation, most cited first.

Study Year Design Participants
Alterations in Brain and Immune Function Produced by Mindfulness Meditation Healthy employees in a work environment 2003 Randomized controlled trial n = 41
Prevention of relapse/recurrence in major depression by mindfulness-based cognitive therapy. Recovered recurrently depressed patients 2000 Randomized controlled trial n = 145
Open hearts build lives: Positive emotions, induced through loving-kindness meditation, build consequential personal resources. Working adults 2008 Randomized controlled trial n = 139
Short-term meditation training improves attention and self-regulation Undergraduate Chinese students 2007 Randomized controlled trial n = 40
Mindfulness-Based Cognitive Therapy for Depression: Replication and Exploration of Differential Relapse Prevention Effects. Recovered recurrently depressed patients 2004 Randomized controlled trial n = 73

Citations in the library

Cited by 34

and 29 more in the library

Cites 18

and 13 more in the library

Explore topics